Last reviewed · How we verify
Serology SARS-CoV2 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Serology SARS-CoV2 (Serology SARS-CoV2) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Serology SARS-CoV2 TARGET | Serology SARS-CoV2 | Assistance Publique - Hôpitaux de Paris | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Serology SARS-CoV2 CI watch — RSS
- Serology SARS-CoV2 CI watch — Atom
- Serology SARS-CoV2 CI watch — JSON
- Serology SARS-CoV2 alone — RSS
Cite this brief
Drug Landscape (2026). Serology SARS-CoV2 — Competitive Intelligence Brief. https://druglandscape.com/ci/serology-sars-cov2. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing